AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32440750 — intervention group
Group type: COMPARATOR
Intervention: 35% HP
Number of subjects: 36
Study 33167920 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-141 30 mg once a day
Number of subjects: 216
Study 33167920 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-141 60 mg once a day
Number of subjects: 216
Study 33167920 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-141 120 mg (60 mg twice a day)
Number of subjects: 216
Study 33167920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 33715574 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous UST
Number of subjects: 71
Study 33715574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed UST
Number of subjects: 71
Study 33715574 — intervention group
Group type: EXPERIMENTAL
Intervention: UST combined with TENS
Number of subjects: 71
Study 33715574 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo UST
Number of subjects: 71
Study 34081779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 81
Study 34081779 — intervention group
Group type: COMPARATOR
Intervention: Headache education
Number of subjects: 81
Study 34081779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction or Headache education
Number of subjects: 81
Study 32826324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 251
Study 32826324 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 251
Study 32826324 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PLEX)
Number of subjects: 251
Study 35552788 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-day antibiotic treatment
Number of subjects: 186
Study 35552788 — intervention group
Group type: COMPARATOR
Intervention: 15-day antibiotic treatment
Number of subjects: 186
Study 34270458 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (specific vaccines and dosages not mentioned)
Number of subjects: 0
Study 34270458 — intervention group
Group type: EXPERIMENTAL
Intervention: Target trial emulation methodology
Number of subjects: 0
Study 32251012 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized hearing intervention
Number of subjects: 21
Study 35079115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily for 8 weeks, followed by bicalutamide 50 mg/day
Number of subjects: 29
Study 35079115 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg/day alone (after 8 weeks of observation)
Number of subjects: 29
Study 35079115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and bicalutamide
Number of subjects: 29
Study 35079115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 29
Study 34096172 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific drill templates (PDT)
Number of subjects: 10
Study 34096172 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided freehand technique
Number of subjects: 10
Study 32005192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1g
Number of subjects: 4524
Study 32005192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study 34922898 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC) diagnostic pathway (n = 393)
Number of subjects: 820
Study 34922898 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS) in addition to routine care (n = 427)
Number of subjects: 820
Study 32770693 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-plane MFU-V treatment (4 MHz/4.5 mm transducer)
Number of subjects: 30
Study 32770693 — intervention group
Group type: COMPARATOR
Intervention: Dual-plane MFU-V treatment (4 MHz/4.5 mm and 7 MHz/3.0 mm transducer)
Number of subjects: 30
Study 36128684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine plus active 'automated self‐association training' (ASAT)
Number of subjects: 154
Study 36128684 — intervention group
Group type: COMPARATOR
Intervention: Saline plus active ASAT
Number of subjects: 154
Study 36128684 — intervention group
Group type: COMPARATOR
Intervention: Ketamine plus sham ASAT
Number of subjects: 154
Study 33358891 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic model (age, prostate-specific antigen, clinical T stage, biopsy GGG, percentage of positive cores)
Number of subjects: 4048
Study 33358891 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model (age, prostate-specific antigen, clinical T stage, biopsy GGG, prostate volume, percentage of tumor within all biopsy cores)
Number of subjects: 4048
Study 33358891 — intervention group
Group type: COMPARATOR
Intervention: NCCN IR PCa stratification
Number of subjects: 4048
Study 33358891 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic model
Number of subjects: 4048
Study 33358891 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model
Number of subjects: 4048
Study 37720054 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 528
Study 37720054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528
Study 36455988 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital adherence technologies (DATs) based behavioural support programme
Number of subjects: 0
Study 36455988 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated care targeting high-risk patients
Number of subjects: 0
Study 32490686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 32490686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36049477 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based cART
Number of subjects: 281
Study 36049477 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-based cART
Number of subjects: 281
Study 35644803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) with flow: 50 L/min and FIO2 of 1.0
Number of subjects: 32
Study 35644803 — intervention group
Group type: COMPARATOR
Intervention: Ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min)
Number of subjects: 32
Study 32520874 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine™ device
Number of subjects: 8
Study 32520874 — intervention group
Group type: COMPARATOR
Intervention: Sham control condition (breathing room air)
Number of subjects: 8
Study 36351727 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (ciprofloxacin and metronidazole) added to surgical drainage of perianal abscess
Number of subjects: 298
Study 36351727 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage alone
Number of subjects: 298
Study 34085779 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous Ig (IgPro20; Hizentra®)
Number of subjects: 171
Study 34085779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 171
Study 32785245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Facilitating Intervention (AFI) - short video showing an example of blended therapy
Number of subjects: 284
Study 32785245 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - attention placebo video
Number of subjects: 284
Study 32785245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Facilitating Intervention (AFI)
Number of subjects: 284
Study 36482813 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service + Interpersonal Communication (SMS + IPC)
Number of subjects: 1394
Study 36482813 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Communication (IPC) only
Number of subjects: 1394
Study 36482813 — intervention group
Group type: EXPERIMENTAL
Intervention: Other intervention groups (not specified)
Number of subjects: 1394
Study 35235958 — intervention group
Group type: EXPERIMENTAL
Intervention: Late preterm ACS
Number of subjects: 660
Study 35235958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ACS for maternal/fetal status
Number of subjects: 660
Study 35235958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ACS for preterm labor
Number of subjects: 660
Study 35235958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ACS in preterm labor
Number of subjects: 660
Study 34687909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing navigation program (including 30-minute visual training and handbook on adverse effects, followed by phone reminders and counseling for 7 weeks)
Number of subjects: 88
Study 34687909 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment approaches (control group)
Number of subjects: 88
Study 33181664 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection
Number of subjects: 0
Study 33181664 — intervention group
Group type: COMPARATOR
Intervention: Sacral canal injection
Number of subjects: 0
Study 34215598 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer unlocked uterine closure
Number of subjects: 2292
Study 34215598 — intervention group
Group type: COMPARATOR
Intervention: Double-layer unlocked uterine closure
Number of subjects: 2292
Study 32140879 — intervention group
Group type: EXPERIMENTAL
Intervention: UO/TAC (UniORV)
Number of subjects: 8
Study 32140879 — intervention group
Group type: COMPARATOR
Intervention: Crystalline TAC (control)
Number of subjects: 8
Study 34144145 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (12 weekly sessions)
Number of subjects: 60
Study 34144145 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 60
Study 36047065 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 3 g, twice/day, orally for 12 weeks
Number of subjects: 94
Study 36047065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 32440731 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1.32×10^11 CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Bifidobacterium animalis, and Bifidobacterium longum daily)
Number of subjects: 40
Study 32440731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 32440731 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 40
Study 33441352 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback intervention (OPEN Stewardship)
Number of subjects: 150
Study 33441352 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (control group)
Number of subjects: 150
Study 32400356 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel mass drug administration (MDA)
Number of subjects: 0
Study 32400356 — intervention group
Group type: EXPERIMENTAL
Intervention: Four annual rounds of praziquantel MDA
Number of subjects: 0
Study 32400356 — intervention group
Group type: COMPARATOR
Intervention: No praziquantel MDA
Number of subjects: 0
Study 32598751 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day)
Number of subjects: 210
Study 32598751 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with bismuth (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day)
Number of subjects: 210
Study 32598751 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy without bismuth (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day, Metronidazole 500 mg 2 times a day)
Number of subjects: 210
Study 36295622 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 83
Study 36295622 — intervention group
Group type: COMPARATOR
Intervention: Control (no ESPB)
Number of subjects: 83
Study 33348047 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive-anodal tDCS
Number of subjects: 54
Study 33348047 — intervention group
Group type: COMPARATOR
Intervention: Repetitive-sham
Number of subjects: 54
Study 33348047 — intervention group
Group type: COMPARATOR
Intervention: Interleaved-sham
Number of subjects: 54
Study 35187781 — intervention group
Group type: EXPERIMENTAL
Intervention: BBL treatment and intradermal injection of BTX
Number of subjects: 22
Study 35187781 — intervention group
Group type: COMPARATOR
Intervention: BBL treatment and intradermal injection of normal saline
Number of subjects: 22
Study 34444714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (group A)
Number of subjects: 44
Study 34444714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance strength training (group B)
Number of subjects: 44
Study 32660530 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic IVH evacuation surgery
Number of subjects: 956
Study 32660530 — intervention group
Group type: COMPARATOR
Intervention: External ventricular drainage (EVD)
Number of subjects: 956
Study 33857940 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin Adsorbent (EA) therapy
Number of subjects: 6
Study 33111988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2.5 mg chip (ChxC) as an adjunctive treatment to subgingival debridement
Number of subjects: 290
Study 33111988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2.5 mg chip (ChxC)
Number of subjects: 290
Study 33111988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine chips)
Number of subjects: 290
Study 36460267 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 526
Study 36460267 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP Adherence Support Services (PASS)
Number of subjects: 526
Study 33913745 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-led self-attachment breastfeeding support intervention
Number of subjects: 504
Study 33913745 — intervention group
Group type: COMPARATOR
Intervention: Standard postpartum care
Number of subjects: 504
Study 32379217 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg E4
Number of subjects: 257
Study 32379217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 36201639 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV-filtering contact lens
Number of subjects: 61
Study 36201639 — intervention group
Group type: COMPARATOR
Intervention: Clear contact lens (control)
Number of subjects: 61
Study 32748765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (audits, live lessons, e-learning, posters, photo contest)
Number of subjects: 66
Study 32748765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 66
Study 32748765 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 66
Study 35326333 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 42
Study 35326333 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 42
Study 32294698 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Cycle Ergometry (PCE)
Number of subjects: 35
Study 32294698 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 35
Study 32294698 — intervention group
Group type: EXPERIMENTAL
Intervention: FES with PCE
Number of subjects: 35
Study 32294698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 35788255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (n=20)
Number of subjects: 45
Study 35788255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 45
Study 35788255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 45
Study 34629442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic OTO-313
Number of subjects: 30
Study 34629442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32907576 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol (50-2100 μg)
Number of subjects: 16
Study 32907576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 35777814 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 119
Study 35777814 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 119
Study 35777814 — intervention group
Group type: EXPERIMENTAL
Intervention: No ULT
Number of subjects: 119
Study 34031023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (ZOLL® Proteus™ intravascular cooling system)
Number of subjects: 111
Study 34031023 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 34031023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 111
Study 34236413 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 330
Study 34236413 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 330
Study 32000798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligohydramnios (defined as Amniotic Fluid Index < 5 cm)
Number of subjects: 12940
Study 32000798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligohydramnios
Number of subjects: 12940
Study 35043571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate dressings with silver and high-G cellulose
Number of subjects: 65
Study 35043571 — intervention group
Group type: COMPARATOR
Intervention: Simple gauges (Control)
Number of subjects: 65
Study 33428906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video
Number of subjects: 225
Study 33428906 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 225
Study 34923618 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 120
Study 34923618 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 120
Study 35997105 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units of cryoprecipitate added to routine treatments
Number of subjects: 54
Study 35997105 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments without cryoprecipitate
Number of subjects: 54
Study 34766913 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE smartphone intervention used from T1 to T2
Number of subjects: 315
Study 34766913 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (received CORE from T2 to T3)
Number of subjects: 315
Study 32328834 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased soluble IL-6R (s-IL-6R) levels (per 1 standard deviation)
Number of subjects: 0
Study 34608564 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited endocrinology eConsultation
Number of subjects: 161
Study 33621788 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK2V617F mutation positive
Number of subjects: 3643
Study 33621788 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelofibrosis patients
Number of subjects: 3643
Study 33621788 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD2 T allele
Number of subjects: 3643
Study 32531432 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus 71 (EV71) vaccine
Number of subjects: 50
Study 36374629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail remodeling with acrylics
Number of subjects: 20
Study 36374629 — intervention group
Group type: COMPARATOR
Intervention: Nail retraining using gauze bandaging
Number of subjects: 20
Study 33657870 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP‐GLB
Number of subjects: 122
Study 33657870 — intervention group
Group type: COMPARATOR
Intervention: FIP
Number of subjects: 122
Study 33657870 — intervention group
Group type: COMPARATOR
Intervention: BBBL
Number of subjects: 122
Study 33657870 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 122
Study 32252094 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 40776
Study 32252094 — intervention group
Group type: COMPARATOR
Intervention: Control (no scopolamine)
Number of subjects: 40776
Study 36410776 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game intervention played at will during 3 months
Number of subjects: 186
Study 36410776 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 186
Study 36410776 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game intervention
Number of subjects: 186
Study 32077057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glulisine
Number of subjects: 12
Study 32077057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35944042 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention designed to improve the quality of healthcare and health insurance services
Number of subjects: 64
Study 35944042 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 64
Study 34696733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided psoas compartment block (PCB) with bupivacaine 0.125% 6-8 ml/h
Number of subjects: 90
Study 34696733 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 90
Study 34696733 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 90
Study 32404742 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplemented with 100 mg bovine lactoferrin (bLf)
Number of subjects: 0
Study 32404742 — intervention group
Group type: COMPARATOR
Intervention: Probiotics without bovine lactoferrin (bLf)
Number of subjects: 0
Study 36274258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sugar claim
Number of subjects: 501
Study 36274258 — intervention group
Group type: COMPARATOR
Intervention: No claim control
Number of subjects: 501
Study 33079313 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-item Headache Impact Test (HIT-6)
Number of subjects: 1072
Study 35817738 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection with oxytocin
Number of subjects: 60
Study 35817738 — intervention group
Group type: COMPARATOR
Intervention: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection (Control)
Number of subjects: 60
Study 33906853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times per day for 16 weeks
Number of subjects: 269